Neurosense Therapeutics Ltd stock is traded at $1.78, with a volume of 51,957. It is down -10.10% in the last 24 hours and down -48.85% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Previous Close:
$1.98
Open:
$1.98
24h Volume:
51,957
Relative Volume:
0.74
Market Cap:
$3.38M
Revenue:
-
Net Income/Loss:
-$10.21M
P/E Ratio:
-
EPS:
-$0.5842
Net Cash Flow:
-$4.10M
1W Performance:
+27.60%
1M Performance:
-48.85%
6M Performance:
-89.32%
1Y Performance:
-90.53%
1-Day Range:
$1.70$2.17
1-Week Range:
$1.30$2.17
52-Week Range:
$1.10$25.40
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS